Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treatment choices in thyroid cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 1191

Prof Makoto Tahara - National Cancer Center Hospital East, Kashiwanoha, Japan

Prof Tahara talks with ecancer at the ESMO 2017 Congress in Madrid about existing treatments of thyroid cancer, including radioactive iodine treatment and surgery.

He notes the clinical activity of some cytotoxic drugs in treating thyroid cancer, but that sorafenib and lenvatinib offer significant improvement of progression free survival with a better toxicity profile, leading to approval. 

Prof Tahara details the comparative success of lenvatinib as a potential treatment choice for radio-iodine resistant thyroid cancer, based on results from the SELECT trial, describing associated toxicity as manageable, and that PFS in this trial favoured shorter durations of drug interaction.

This programme has been supported by an unrestricted educational grant from Eisai.


Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence